重症肢体缺血再次远端旁路术的长期结果与风险分析
单中心回顾性分析2009至2018年因重症肢体缺血行再次远端旁路术(rDB)的44例患者(46次手术),并与初次远端旁路术(iDB)比较。rDB的一期和二期通畅率显著低于iDB,部分与大隐静脉使用减少和流出道较差有关。二次通畅率受iDB移植物通畅持续时间影响,早期闭塞(<6个月)者预后差,rDB应视为次优选择。
要点
- rDB的一期和二期通畅率显著低于iDB。
- iDB移植物通畅持续时间是rDB二期通畅率的独立风险因素。
- iDB术后6个月内早期闭塞者rDB预后极差,应谨慎选择。
核心结论
- rDB的通畅率显著低于iDB,部分原因是大隐静脉使用较少和流出道较差。
- rDB术后生存率和移植物通畅率均较低,尤其对于iDB术后6个月内早期闭塞的患者,rDB应作为次优治疗选择。
研究设计与样本
- 单中心回顾性研究,纳入2009至2018年因CLI行rDB的44例患者(46次手术),并与310次iDB(251例患者)进行比较。
- 分析手术细节、一期和二期通畅率、生存率、免于大截肢率及影响通畅率的风险因素。
- 流出道采用膝下GLASS分级(0-4级,0代表流出道好,4代表流出道最差)评估。
主要发现
- rDB患者中男性27例,平均年龄75±10岁,糖尿病77%,慢性肾功能衰竭血液透析45%。
- rDB全部使用自体静脉:大隐静脉28例(57%)、小隐静脉13例(27%)、臂静脉6例(12%)、股浅静脉2例(4%)。
- rDB的大隐静脉使用率低于iDB(57% vs. 90%,P < 0.0001),膝下GLASS 4级比例高于iDB(76% vs. 60%,P = 0.04)。
- rDB的一期和二期通畅率分别为1年25%和44%、3年14%和29%,均显著低于iDB(P < 0.0001)。
- rDB术后1年生存率68%、3年53%;免于大截肢率1年83%、3年66%。
临床怎么用
- 对于iDB术后需行rDB的CLI患者,应充分评估大隐静脉可用性和流出道情况。
- iDB术后6个月内早期闭塞的患者行rDB预后极差,应谨慎选择或考虑替代方案。
- rDB术后需密切监测移植物通畅率,尤其关注二期通畅率。
局限性
- 单中心回顾性研究,样本量较小(rDB仅46次手术)。
- 未报告其他可能影响通畅率的因素如抗血小板药物使用等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Distal bypass is the optimal treatment for patients with critical limb ischemia (CLI). However, effectiveness of redo distal bypass (rDB) after failed initial distal bypass (iDB) remains uncertain. This study aimed to analyze long-term results of rDB for CLI. METHODS: Patients undergoing rDB for CLI from 2009 to 2018 at a single institute were retrospectively reviewed. Operative details, primary and secondary patency, survival rate, major amputation-free rate, and risk factors affecting patency were analyzed. The distal runoff was evaluated using the infrapopliteal Global Limb Anatomic Staging System (GLASS) grade (0 to 4: 0 represents good runoff and 4 represents the poorest runoff). RESULTS: Of 310 iDB (251 patients), 46 rDB were performed in 44 patients: 27 men, mean age 75 ± 10 years, diabetes mellitus 77%, chronic renal failure with hemodialysis 45%. Only the autologous veins were used in distal bypasses: a great saphenous vein (GSV) in 28 (57%), a small saphenous vein in 13 (27%), an arm vein in 6 (12%), and a superficial femoral vein in 2 (4%). The GSV was used less frequently for rDB than for iDB (57% vs. 90%, P < 0.0001). The infrapopliteal GLASS grade 4 was recognized more in rDB than iDB (76% vs. 60%, P = 0.04). Primary and secondary patency of rDB was 25% and 44% at 1 year and 14% and 29% at 3 years, respectively, which were significantly lower than those of iDB (P < 0.0001). The survival rate after rDB was 68% at 1 year and 53% at 3 years. Freedom from major amputation rate in rDB was 83% at 1 year and 66% at 3 years. Multivariate analysis showed the risk factor influencing on secondary patency was patent duration of the iDB graft (P = 0.012). Secondary patency of rDB was higher in the group of late graft occlusion ≥6 months after iDB (late group) than in the group of early graft occlusion < 6 months after iDB (early group) (94% vs. 9% at 1 year and 75% vs. 5% at 3 years, P < 0.0001). However, freedom from major amputation rate at 3 years was comparable between both groups (71% in the late group vs. 61% in the early group). CONCLUSIONS: Patency of rDB was significantly lower than that of iDB partly because of less use of the GSV and poorer runoff. Because survival and graft patency after rDB was low, rDB should be a suboptimal treatment especially in patients with early graft occlusion within 6 months after iDB.
引用
- Kobayashi T, Hamamoto M, Ozawa M, et al. Long-Term Results and Risk Analysis of Redo Distal Bypass for Critical Limb Ischemia. Ann Vasc Surg. 2020. PMID: 32335252. doi:10.1016/j.avsg.2020.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。